In a phase III trial, vadadustat was noninferior to darbepoetin alfa in increasing and maintaining Hb within the target range up to week 52 and was generally well tolerated in patients with non-dialysis-dependent CKD [8]. The gene discussed is GSTM1; the disease is chronic kidney disease.